Table 2 Spondyloarthritis features, pharmacological treatment, and PROMs in AS, PsA or other-SpA, with IBP

Age 2009, mean (sd)^b

54 (13)

57 (13)

53 (15)

Sex, N men (%)^b

182 (57)

129 (32)

<0.001

87 (31)

<0.001

0.860

Uveitis^b

63 (20)

9 (2)

<0.001

37 (13)

<0.001

<0.001

Psoriasis^b

19 (6)

407 (100)

<0.001

0

Inflammatory bowel disease^b

25 (8)

21 (5)

0.901

36 (13)

0.706

0.001

NRS-spinal pain^c

5.9 (5.6−6.1)

6.1 (5.9−6.4)

0.068

6.2 (6.0−6.5)

0.037

0.688

NRS-fatigue^c

5.8 (5.6−6.1)

6.2 (5.9−6.4)

0.044

6.1 (5.8−6.4)

0.117

0.547

NRS-patients global^c,d

5.2 (4.9−5.4)

5.4 (5.2−5.6)

0.188

5.5 (5.2−5.7)

0.087

0.850

BASDAI^c

5.1 (4.8−5.3)

5.7 (5.5−5.8)

<0.001

5.5 (5.3−5.8)

0.006

0.530

BASFI^c

4.4 (4.2−4.7)

4.8 (4.5−5.0)

0.093

4.4 (4.1−4.7)

0.973

0.093

EQ-5D^c

0.68 (0.66−0.70)

0.65 (0.63−0.67)

0.062

0.67 (0.64−0.69)

0.362

0.421

Etanercept^b

27 (9)

54 (13)

0.044

15 (5)

0.150

0.001

Adalimumab^b

12 (4)

32 (8)

0.027

9 (3)

0.825

0.013

Methotrexate^b

37 (12)

151 (37)

<0.001

33 (12)

1.000

<0.001

Sulphasalazine^b

28 (9)

14 (3)

0.003

24 (9)

1.000

0.006